Skip to main content

3 Result(s)

within Yenny Angela Remove this filter

and

  1. Article

    Open Access

    Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

    Adjuvant treatment with immune checkpoint inhibitors, such as PD1-antibodies (ICI) ± CTLA4-antibodies (cICI) or targeted therapy with BRAF/MEK inhibitors (TT), has shown a significant improvement in disease-fr...

    Katharina C. Kähler, Ralf Gutzmer… in Journal of Cancer Research and Clinical On… (2024)

    Download PDF (1095 KB) View Article

  2. No Access

    Article

    Aktuelle Behandlung des fortgeschrittenen Melanoms

    In der medikamentösen Behandlung des fortgeschrittenen kutanen und mukosalen Melanoms hat es in den letzten 10 Jahren wegweisende Verbesserungen gegeben. Diese Verbesserungen wurden erzielt durch den Einsatz v...

    Prof. Dr. med. Ralf Gutzmer, Yenny Angela, Mareike Alter in Der Onkologe (2022)

  3. No Access

    Article

    Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases

    PD-1 inhibition (PD-1i) is the standard of care in melanoma and other malignancies. In patients with bone metastases of solid tumors, the monoclonal antibody denosumab directed against RANKL is approved for th...

    Yenny Angela, Sebastian Haferkamp, Carsten Weishaupt… in Cancer Immunology, Immunotherapy (2019)